An Approach to Breast Cancer Diagnosis via PET Imaging of Microcalcifications Using (18)F-NaF.

Abstract

UNLABELLED:

Current radiologic methods for diagnosing breast cancer detect specific morphologic features of solid tumors or any associated calcium deposits. These deposits originate from an early molecular microcalcification process of 2 types: type 1 is calcium oxylate and type II is carbonated calcium hydroxyapatite. Type I microcalcifications are associated mainly with benign tumors, whereas type II microcalcifications are produced internally by malignant cells. No current noninvasive in vivo techniques are available for detecting intratumoral microcalcifications. Such a technique would have a significant impact on breast cancer diagnosis and prognosis in preclinical and clinical settings. (18)F-NaF PET has been used solely for bone imaging by targeting the bone hydroxyapatite. In this work, we provide preliminary evidence that (18)F-NaF PET imaging can be used to detect breast cancer by targeting the hydroxyapatite lattice within the tumor microenvironment with high specificity and soft-tissue contrast-to-background ratio while delineating tumors from inflammation.

METHODS:

Mice were injected with approximately 10(6) MDA-MB-231 cells subcutaneously and imaged with (18)F-NaF PET/CT in a 120-min dynamic sequence when the tumors reached a size of 200-400 mm(3). Regions of interest were drawn around the tumor, muscle, and bone. The concentrations of radiotracer within those regions of interest were compared with one another. For comparison to inflammation, rats with inflamed paws were subjected to (18)F-NaF PET imaging.

RESULTS:

Tumor uptake of (18)F(-) was significantly higher (P < 0.05) than muscle uptake, with the tumor-to-muscle ratio being about 3.5. The presence of type II microcalcification in the MDA-MB-231 cell line was confirmed histologically using alizarin red S and von Kossa staining as well as Raman microspectroscopy. No uptake of (18)F(-) was observed in the inflamed tissue of the rats. Lack of hydroxyapatite in the inflamed tissue was verified histologically.

CONCLUSION:

This study provides preliminary evidence suggesting that specific targeting with (18)F(-) of hydroxyapatite within the tumor microenvironment may be able to distinguish between inflammation and cancer.

• Authors: George H Wilson 3rd, John C Gore, Thomas E Yankeelov, Stephanie Barnes, Todd E Peterson, Jarrod M True, Sepideh Shokouhi, J Oliver McIntyre, Melinda Sanders, Vandana Abramson, The-Quyen Ngyuen, Anita Mahadevan-Jansen, Mohammed N Tantawy
• Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 55 Issue 7 Pg. 1138-43 (Jul 2014) ISSN: 1535-5667 [Electronic] United States
• PMID: 24833491 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Chemical References

• Fluorine Radioisotopes
• Sodium Fluoride
• Durapatite

Topics

• Animals
• Breast Neoplasms (complications, diagnostic imaging, metabolism, pathology)
• Calcinosis (complications)
• Cell Line, Tumor
• Durapatite (metabolism)
• Female
• Fluorine Radioisotopes
• Humans
• Mice
• Positron-Emission Tomography
• Sodium Fluoride